Join our live webinar with Dr. Saverio Tedesco, as he discusses his current work at University College London (UCL) on the human artificial chromosomes (HACs) and iPS cells for modeling muscular dystrophies. Dr. Tedesco’s group is interested in understanding how skeletal muscle sustains tissue regeneration and how this process could be improved to develop therapies for incurable diseases such as muscular dystrophies. Current research projects include investigating the extension of the HAC-based genetic correction platform to human myogenic progenitors; the use of small molecules to reprogram muscle stem cell properties for cell therapies; and the use of iPS cell-derived myogenesis for disease modeling, tissue engineering and ex vivo gene and cell therapy.
Dr. Francesco Saverio Tedesco
Principal Research Associate and NIHR Academic Clinical Fellow in Paediatrics
University College London (UCL), UK
Live Webinar - Human Artificial Chromosomes and iPS Cells: "Reprogramming" Experimental Therapies for Muscle Diseases
Wednesday April 26th, 2017 - 10AM PST | 1PM EST | 6PM UTC
If you are unable to attend the live webinar, please register and we will send you a link to view the recording when it becomes available.
- Overview on muscle stem cells and regeneration
- Limitations for gene and cell therapy for muscular dystrophies
- Human artificial chromosomes and iPS cells to bypass aforementioned hurdles
- Extension of the same technologies to disease modeling, drug screening and tissue engineering
Francesco Saverio Tedesco, MD, PhD, FHEA, is a Principal Research Associate and NIHR Academic Clinical Fellow in Paediatrics at University College London (UCL), UK. The Tedesco Lab focuses on the study of muscle regeneration and on the development of novel gene and cell therapy strategies for muscle disorders. Dr. Tedesco graduated in Medicine and Surgery with honors at the University of Rome “La Sapienza” (Italy). He then continued his studies in the laboratory of Professor Giulio Cossu at San Raffaele Scientific Institute (Milan, Italy), where he obtained his PhD in 2010 studying novel gene and cell therapy strategies for muscular dystrophy. After his PhD, he coupled post-doctoral research in muscle regeneration with clinical training between Italy (San Raffaele Hospital, Milan) and UK (University College London and UCL Hospitals). Additionally, Dr. Tedesco became a co-investigator in a first-in-human clinical trial based upon transplantation of donor muscle progenitor cells for Duchenne muscular dystrophy (EudraCT no. 2001-000176-33). Dr. Tedesco joined UCL Department of Cell and Developmental Biology in January 2012, and in 2014, he established his independent research group.
This webinar is part of our webinar series in the Pluripotent Learning Lounge
, where key figures in the hPSC field discuss their recent research findings.